Chimera Research Group

previous arrow
next arrow
Slider

June 12th Biotech Update

As perhaps the least surprising news of the day, inflation came in cooler than expected, rates are moving lower, and the sector seems to be rallying.  While perhaps the lower inflation is a bit of a surprise, the reaction should not surprise anyone as this has been the relationship for a couple of years.  I […]

June 10th Biotech Update

Keeping on the theme of griding we continue to work through the ASCO and other data.  The sector is still going to be linked to rates and the Fed but given that we are not in a place for rates to go down, we are looking likely to grind away at these levels.  I thought […]

June 5th Biotech Update

Not a bad start to the week.  It is a nice little move higher but we are still in a grinding sort of market.  I am perfectly content to let the sector build a nice long base at these levels.  Of course, these can be double edged swords.  It will be a very strong base […]

June 3rd Biotech Update

We are sort of hanging out at these levels.  Perhaps we have a modest little downtrend but I sort of see the sector more in a holding pattern more than anything else. I know we are waiting for inflation and rates to move down and our expectations are that it helps the sector.  What if […]

Mailing List

Introduction

Overview

Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press

Slider

Log In

JoinLost Password?